Technology Licensing Opportunities
Efficient Development of Orally-Bioavailable Cyclic-Peptide Drugs via Molecular Dynamics + Machine Learning BACKGROUND Cyclic peptides are a promising drug modality, combining beneficial traits from
https://viceprovost.tufts.edu/cyclic-peptide-structure-prediction-structural-ensembles-achieved-molecular-dynamics-and-machine
SUMMARY Researchers at Tufts University discovered novel antigens for a gonococcal vaccine through a unique candidate antigen selection strategy. In vivo, these previously unconsidered protein
https://viceprovost.tufts.edu/new-neisseria-gonorrhoeae-vaccine-antigens-expressed-during-natural-mucosal-infection
SUMMARY A Tufts University investigator and their collaborators at R&D Systems Inc., have developed novel IL-38 analogues to treat neuroinflammatory and neurodegenerative diseases like Autism Spectrum
https://viceprovost.tufts.edu/novel-il-38-analogues-are-potent-inhibitors-neuroinflammatory-mediators
SUMMARY A researcher from the Tufts University School of Medicine has developed novel derivatives of Niacin, which do not produce the uncomfortable side effect of flushing and reddening of the skin
https://viceprovost.tufts.edu/novel-non-flushing-niacin-derivatives-and-mimetics